Primary Mediastinal B Cell Lymphoma
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| kte-c19 | Kite Pharma, Inc. (KITE) |
Frequently asked questions
How many drugs are in development for Primary Mediastinal B Cell Lymphoma?
BioSniper tracks 1 drug in development for Primary Mediastinal B Cell Lymphoma across 1 company.
How many clinical trials target Primary Mediastinal B Cell Lymphoma?
There are 1 clinical trial targeting Primary Mediastinal B Cell Lymphoma tracked by BioSniper.
What is the prevalence of Primary Mediastinal B Cell Lymphoma?
The estimated prevalence of Primary Mediastinal B Cell Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Primary Mediastinal B Cell Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis